Claims

1. A capsule for oral administration that encapsulates a pharmaceutical blend comprising
   (a) 20 – 60 % by weight of the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea in its free base form, present as mono-phosphate salt,
   (b) 0.5 – 5 % by weight of hydroxypropylmethylcellulose,
   (c) 1 – 4 % by weight of crosslinked polyvinylpyrrolidone, and
   (d) a filler selected from the group consisting of a cellulose, lactose, mannitol, and combinations thereof;

   wherein the weight percentages are based on the total weight of the pharmaceutical blend content of the capsule.

2. The capsule of claim 1, wherein the pharmaceutical blend has a poured bulk density of at least 0.4g/mL.

3. The capsule of claim 1, wherein the pharmaceutical blend comprises 30-45% of the drug substance.

4. The capsule of claim 3, wherein the pharmaceutical blend comprises:
   2 – 4 % by weight of hydroxypropylmethylcellulose, and
   2 – 4 % by weight of crosslinked polyvinylpyrrolidone.